Trevi Therapeutics
TRVI
Trevi Therapeutics (TRVI) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.11
- EPS estimate
- −$0.11
- EPS surprise
- −0.46%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.11 | −$0.11 | −0.46% | $0.00 | SEC |
| Q1 2026 | May 5, 2026 | −$0.08 | −$0.09 | −18.89% | $0.00 | SEC |
| Q4 2025 | Mar 17, 2026 | −$0.10 | −$0.06 | +37.89% | $0.00 | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.10 | −$0.08 | +18.62% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.10 | −$0.09 | +13.63% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.12 | −$0.09 | +26.83% | $0.00 | SEC |
| Q4 2024 | Mar 18, 2025 | −$0.13 | −$0.11 | +14.20% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.12 | −$0.13 | −8.79% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.11 | −$0.12 | −10.50% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.09 | −$0.11 | −26.00% | $0.00 | SEC |
| Q4 2023 | Mar 20, 2024 | −$0.09 | −$0.08 | +12.76% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.09 | −$0.08 | +12.76% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.09 | −$0.07 | +17.65% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.07 | −$0.06 | +18.81% | $0.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.11 | −$0.06 | +43.40% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.13 | −$0.12 | +7.69% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.17 | −$0.14 | +18.84% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.26 | −$0.24 | +8.85% | $0.00 | SEC |
| Q4 2021 | Mar 17, 2022 | −$0.30 | −$0.28 | +5.08% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.40 | −$0.34 | +13.92% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Trevi Therapeutics (TRVI) last report earnings?
Trevi Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did TRVI beat earnings estimates?
No. Trevi Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.11 estimate — a 0.46% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.